Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Are hypomethylating agents useful in preventing relapse in AML and MDS?

Marcos de Lima • 26 Oct 2019
COSTEM 2019
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Azacitidine

Marcos de Lima, MD, University Hospitals Cleveland Medical Center, Cleveland, OH, discusses hypomethylating agents and their utility in preventing relapse in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Marcos de Lima

1:08
Point-of-care CAR T-cells
Marcos de Lima • 26 Aug 2020
3:36
Results of a site-manufactured anti-CD19 CAR-T in nHL
Marcos de Lima • 31 Aug 2020
5:15
Outlook on the current CAR-T climate
Marcos de Lima • 1 Sep 2020
5:15
Outlook on the current CAR-T climate
Marcos de Lima • 27 Aug 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals